Nasdaq Welcomes ConforMIS, Inc. to The Nasdaq Stock Market

NEW YORK, July 1, 2015  -- Nasdaq (NDAQ) announced that trading ConforMIS, Inc. (CFMS) commenced on The Nasdaq Stock Market on July 1, 2015.

ConforMIS, Inc. is a medical technology company that develops, manufactures and sells Customized Partial and Total Knee Implants. ConforMIS uses its proprietary iFit(R) Image-to-Implant(R) technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy.

Second Sight Announces Positive Long-Term Results of the Argus II Retinal Prosthesis System

Study Results Published in Top-Tier Journal Ophthalmology

SYLMAR, Calif.--- Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced positive three year results post-implant of its Argus® II Retinal Prosthesis System (“Argus II”) from a multi-center clinical trial.

The paper titled, “Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind”, highlights 30 subjects implanted with the Argus II at 10 centers throughout the United States and Europe.

Lumenis to be Acquired for Approximately $510 Million, $14.00 Per Share, in Cash

YOKNEAM, Israel, June 18, 2015  -- Lumenis Ltd. (LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced today that it has signed a definitive agreement to be acquired by XIO Group for $14.00 per share in cash, for an aggregate purchase price of approximately $510 million.

"This acquisition is a strong recognition and vote of confidence in Lumenis' achievements and its employees, and I am excited about the future prospects of Lumenis," said Tzipi Ozer-Armon, Chief Executive Officer. "Over the past 3 years we have managed to transform Lumenis into a strong, growing and profitable company. We have refocused our strategy, introduced new products, and tripled our EBITDA. Furthermore, we have created a very bright and promising future for Lumenis by building a robust pipeline of innovative products, a strong sales team in each region, and by enhancing our global brand recognition. I am confident that we will continue to thrive and reach new heights together with XIO Group."

PhotoMedex Sells XTRAC® Business to MELA Sciences for $42.5 Million, Pays off All Outstanding Debt

HORSHAM, Pa.--- PhotoMedex, Inc. (NasdaqGS and TASE:PHMD) announces the sale of its worldwide XTRAC® and VTRAC® psoriasis and vitiligo treatment businesses to MELA Sciences, Inc. (Nasdaq:MELA) for $42.5 million in cash. In addition, the company announces it has paid off in full all outstanding debt, which totaled $40.1 million as of June 22, 2015.

“PhotoMedex is now able to focus solely on our core consumer and skincare businesses, including the no!no!™, Kyrobak® and Neova® brands, without the burden of debt payments and the restrictions of forbearance agreements. These highly-regarded and established brands are sold worldwide via direct-to-consumer, retail and distribution channels, and through more than 2,400 U.S. dermatology and plastic surgery offices,” said Dr. Dolev Rafaeli, chief executive officer of PhotoMedex.

TriVascular Technologies, Inc. Announces FDA Approval of Ovation iX(TM) Iliac Stent Graft

Enhancements to Iliac Stent Graft Technology Are Designed to Improve Ease of Use and Expand Patient Applicability

SANTA ROSA, Calif., June 15, 2015 -- TriVascular Technologies, Inc. (TRIV) announced today that the U.S. Food and Drug Administration (FDA) has approved the Ovation iX Iliac Stent Graft for the Ovation Prime(R) Abdominal Stent Graft System, together with manufacturing enhancements that will facilitate a broader commercial launch of the product. Building upon the strength of the Ovation(R) and Ovation Prime iliac technology, the Ovation iX iliac stent graft is engineered to promote patency even in hostile anatomy. Ovation iX stands for integrated exchange, and the iliac stent graft was developed to improve physician ease of use and expand patient applicability. The less invasive, low-profile (10-13F) integrated sheath is designed to minimize vessel trauma. With flared limbs up to 28mm diameter and limb lengths up to 160mm, the broader size matrix and even lower profiles enable treatment of a wider range of AAA anatomies.

Videos / Webinars

View all videos

Stockjunction Members

View All Members